GnRH-a联合左炔诺孕酮宫内缓释系统治疗子宫腺肌病的meta分析

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (1775 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To systematically review the safety and efficacy of gonadotropin-releasing hormone agonist (GnRH-a) combined with Levonorgestrel intrauterine sustained release system (LNG-IUS) in the treatment of adenomyosis (AM). Methods Randomized controlled trials were searched in PubMed, The Cochrane Library, EMBase, Web of Science, CNKI, WanFang, VIP and CBM databases. The retrieval time was from inception to April, 2020. The experimental group was given GnRH-a combined with LNG-IUS, and the control group was given LNG-IUS. The uterine volume, decyclification rate, irregular vaginal bleeding rate and total effective rate after treatment were compared between the two groups. Results A total of 11 literatures involving 845 patients. The results of meta-analysis showed that: the uterine volume of the experimental group was smaller than that of the control group (MD = -34.35, 95%CI: -48.47, -20.23, P < 0.000 01). The decyclification rate in the experimental group was lower than that in the control group (RR = 0.21, 95%CI: 0.11, 0.40, P < 0.000 01). The rate of irregular vaginal bleeding in the experimental group was lower than that in the control group (RR = 0.23, 95%CI: 0.14, 0.40, P < 0.000 01). The total effective rate of the experimental group was higher than that of the control group (RR = 1.23, 95%CI: 1.13, 1.34, P < 0.000 01). Conclusion GnRH-a combined with LNG-IUS can significantly improve the clinical efficacy and safety.

Key words： Adenomyosis Gonadotropin-releasing hormone agonist Levonorgestrel Meta-analysis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Xinchun LIU Zikang LI Hanyu DAI Zeqi BAO Meiru SUN Weiwei ZHAO Ruihua

Cite this article:

YANG Xinchun LIU Zikang LI Hanyu DAI Zeqi BAO Meiru SUN Weiwei ZHAO Ruihua. Meta-analysis of GnRH-a combined with Levonorgestrel intrauterine sustained release system in the treatment of adenomyosis[J]. 中国医药导报, 2021, 18(2): 73-76.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2021/V18/I2/73

[1] Struble J，Reid S，Bedaiwy MA. Adenomyosis：A Clinical Review of a Challenging Gynecologic Condition [J]. J Minim Invasive Gynecol，2016，23（2）：164-185.
[2] 郎景和.子宫腺肌病的若干问题[J].中国实用妇科与产科杂志，2017，33（2）：129-133.
[3] de Bruijn AM，Lohle PN，Huirne JA，et al. Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Adenomyosis：Protocol for the Randomized QUESTA Trial [J]. JMIR Res Protoc，2018，7（3）：e47.
[4] 李雷，冷金花.子宫腺肌病对生育影响及治疗研究进展[J].中国实用妇科与产科杂志，2012，28（12）：953-955.
[5] 彭超，周应芳.子宫腺肌病药物治疗选择及长期管理[J].中国实用妇科与产科杂志，2019，35（5）：516-519.
[6] 中华医学会妇产科学分会子宫内膜异位症协作组.子宫内膜异位症的诊治指南[J].中华妇产科杂志，2015，50（3）：161-169.
[7] Higgins JPT，Thomas J，Chandler J，et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.0（updated July 2019）[J]. Cochrane，2019. Available from www.training.cochrane.org/handbook.
[8] 伍玉萍.促性腺激素释放激素激动剂、左炔诺孕酮宫内缓释系统联用对子宫腺肌病的治疗价值观察[J].养生保健指南，2018（7）：313.
[9] 张冬雅，郭红军，邱海峰.GnRH-α联合曼月乐治疗子宫腺肌症患者的疗效及对血清复发相关指标的影响[J].实用医学杂志，2019（1）：84-87.
[10] 张鹏雁.促性腺激素释放激素激动剂联合曼月乐治疗子宫腺肌症的临床效果分析[J].中国医学工程，2018， 26（11）：56-59.
[11] 李爱萍.促性腺激素释放激素激动剂及左炔诺孕酮宫内缓释系统辅助治疗子宫腺肌病的效果及对痛经程度及生存质量的影响[J].中国妇幼保健，2018（7）：1478-1480.
[12] 杨洋.LNG-IUS联合GnRH-a治疗子宫腺肌病的临床疗效观察[J].中国妇幼保健，2019，34（23）：5385-5387.
[13] 杨莉.LNG-IUS联用注射用醋酸亮丙瑞林微球治疗子宫腺肌症的疗效[J].中国合理用药探索，2019，16（10）：35-38.
[14] 栗琼，左馨，张俊.醋酸亮丙瑞林联合曼月乐治疗子宫腺肌病48例临床分析[J].吉林医学，2019，40（6）：1304-1305.
[15] 梁沙沙.曲普瑞林联合左炔诺孕酮宫内缓释系统治疗子宫腺肌症的疗效观察[J].中国民康医学，2019，31（7）：87-89.
[16] 王孙英，张红芸.两种药物联合治疗70例子宫腺肌病的对比研究[J].上海预防医学，2015，27（2）：105-107.
[17] 王晓霞，李慧敏，姚婷婷，等.曼月乐联合达菲林、优思明治疗子宫腺肌症的临床疗效观察[J].中国实用医药，2016，11（26）：258-259.
[18] 覃卫玲，廖婕洁.注射用醋酸曲普瑞林联合左炔诺孕酮宫内节育系统对子宫腺肌病患者子宫血流动力学、卵巢功能及安全性的影响[J].中国医院用药评价与分析，2019，19（5）：546-548，551.
[19] Vannuccini S，Luisi S，Tosti C，et al. Role of medical therapy in the management of uterine adenomyosis [J]. Fertil Steril，2018，109（3）：398-405.
[20] Baboo Kalianee Devi，陈正云，张信美.子宫腺肌病患者药物治疗进展[J].浙江大学学报：医学版，2019，48（2）：142-147.
[21] 郎景和，冷金花，邓姗，等.左炔诺孕酮宫内缓释系统临床应用的中国专家共识[J].中华妇产科杂志，2019（12）：815-816.
[22] Abbas AM，Samy A，Atwa K，et al. The role of levonorgestrel intra-uterine system in the management of adenomyosis：A systematic review and meta-analysis of prospective studies [J]. Acta Obstet Gynecol Scand，2020，99（5）：571-581.
[23] 张丽凤，杨慧，张信美，等.左炔诺孕酮宫内节育系统治疗子宫腺肌病患者的疗效和不良反应观察[J].浙江大学学报：医学版，2019，48（2）：130-135.
[24] Zhang P，Song K，Li L，et al. Efficacy of combined levonorgestrel-releasing intrauterine system with gonado-tropin-releasing hormone analog for the treatment of adenomyosis [J]. Med Princ Pract，2013，22（5）：480-483.
[25] 李晓红，杜蓉，丁岩.促性腺激素释放激素激动剂治疗左炔诺孕酮缓释系统所致阴道不规则出血的效果[J].中国医药导报，2014，11（21）：17-20.